Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$19.33
+3.4%
$18.81
$10.21
$25.67
$4.46B0.382.30 million shs2.47 million shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$156.98
+2.0%
$140.83
$122.80
$207.84
$4.45B0.7279,487 shs571,859 shs
Metsera Inc. stock logo
MTSR
Metsera
$34.89
+5.8%
$32.59
$12.30
$47.40
$3.47BN/A1.03 million shs2.06 million shs
Pharvaris N.V. stock logo
PHVS
Pharvaris
$20.00
+0.6%
$18.74
$11.51
$26.33
$1.04B-2.81198,380 shs145,311 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
+3.37%+7.33%+6.56%-17.81%+57.41%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
+2.02%+6.35%+11.06%-5.52%-24.70%
Metsera Inc. stock logo
MTSR
Metsera
+5.76%-13.79%+20.89%+36.02%+3,488,999,900.00%
Pharvaris N.V. stock logo
PHVS
Pharvaris
+0.60%-3.01%+12.23%+8.87%+16.69%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
4.2874 of 5 stars
3.73.00.00.03.82.53.1
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
4.8858 of 5 stars
4.52.00.04.73.23.31.9
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/AN/AN/AN/AN/A
Pharvaris N.V. stock logo
PHVS
Pharvaris
1.706 of 5 stars
3.52.00.00.02.10.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
3.33
Buy$27.6743.13% Upside
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
3.00
Buy$211.3334.62% Upside
Metsera Inc. stock logo
MTSR
Metsera
3.00
Buy$55.0057.64% Upside
Pharvaris N.V. stock logo
PHVS
Pharvaris
3.00
Buy$36.2081.00% Upside

Current Analyst Ratings Breakdown

Latest PHVS, ADMA, KRYS, and MTSR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/25/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$240.00
7/25/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$219.00
7/22/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$193.00 ➝ $192.00
7/9/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$155.00 ➝ $176.00
6/24/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$240.00
6/20/2025
Metsera Inc. stock logo
MTSR
Metsera
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$65.00
6/11/2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$32.00
6/10/2025
Metsera Inc. stock logo
MTSR
Metsera
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$56.00 ➝ $62.00
6/5/2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$27.00
5/16/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$215.00 ➝ $155.00
5/14/2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$28.00 ➝ $25.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$426.45M10.82$0.56 per share34.55$1.48 per share13.06
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$290.52M15.62$4.73 per share33.18$32.90 per share4.77
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/A$4.28 per shareN/A
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/AN/AN/AN/A$5.54 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$197.67M$0.8522.7428.01N/A45.01%47.16%30.51%8/6/2025 (Estimated)
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$89.16M$4.1637.7415.57N/A37.17%14.64%13.28%8/4/2025 (Estimated)
Metsera Inc. stock logo
MTSR
Metsera
-$209.13MN/A0.00N/AN/AN/AN/AN/A
Pharvaris N.V. stock logo
PHVS
Pharvaris
-$145.24M-$3.01N/AN/AN/AN/A-54.02%-50.36%8/13/2025 (Estimated)

Latest PHVS, ADMA, KRYS, and MTSR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q1 2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
-$0.87N/AN/AN/AN/AN/A
8/6/2025Q2 2025
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$0.14N/AN/AN/A$121.77 millionN/A
8/4/2025Q2 2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.20N/AN/AN/A$95.42 millionN/A
7/28/2025Q2 2025
Metsera Inc. stock logo
MTSR
Metsera
N/A-$0.66N/A-$0.66N/AN/A
5/13/2025Q1 2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
-$0.80-$0.89-$0.09-$0.89N/AN/A
5/12/2025Q1 2025
Metsera Inc. stock logo
MTSR
Metsera
N/A-$1.03N/A-$1.03N/AN/A
5/7/2025Q1 2025
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$0.16$0.14-$0.02$0.11$116.40 million$114.80 million
5/6/2025Q1 2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.38$1.20-$0.18$1.20$98.66 million$88.18 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
N/AN/AN/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/AN/A
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
0.22
6.58
3.36
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
9.65
9.27
Metsera Inc. stock logo
MTSR
Metsera
N/A
5.26
6.55
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/A
11.10
11.10

Institutional Ownership

CompanyInstitutional Ownership
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
75.68%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
86.29%
Metsera Inc. stock logo
MTSR
Metsera
N/A
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/A

Insider Ownership

CompanyInsider Ownership
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
3.50%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
13.70%
Metsera Inc. stock logo
MTSR
Metsera
N/A
Pharvaris N.V. stock logo
PHVS
Pharvaris
11.84%
CompanyEmployeesShares OutstandingFree FloatOptionable
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
530238.73 million230.38 millionOptionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
21028.90 million24.94 millionOptionable
Metsera Inc. stock logo
MTSR
Metsera
81105.06 millionN/AN/A
Pharvaris N.V. stock logo
PHVS
Pharvaris
3052.29 million46.10 millionNot Optionable

Recent News About These Companies

Pharvaris secures $175 million public offering

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA Biologics stock logo

ADMA Biologics NASDAQ:ADMA

$19.33 +0.63 (+3.37%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$19.48 +0.16 (+0.80%)
As of 08/1/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Krystal Biotech stock logo

Krystal Biotech NASDAQ:KRYS

$156.98 +3.11 (+2.02%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$159.00 +2.02 (+1.29%)
As of 08/1/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Metsera stock logo

Metsera NASDAQ:MTSR

$34.89 +1.90 (+5.76%)
As of 08/1/2025 04:00 PM Eastern

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

Pharvaris stock logo

Pharvaris NASDAQ:PHVS

$20.00 +0.12 (+0.60%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$20.08 +0.07 (+0.37%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.